Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
Silvia De FranciaPaola BerchiallaTiziana ArmandoSilvana StortoSarah AllegraVeronica SciannameoGiulia SoaveAndrea Elio SprioSilvia RaccaMaria Rosaria CaiaffaLibero CiuffredaMaria Valentina MussaPublished in: European journal of clinical pharmacology (2022)
According to the association of sex chemotherapy agent-related toxicities, females resulted on average at a significant increased risk of more common adverse events (constipation, dysgeusia, alopecia, heartburn, vomit, asthenia, nausea, pain events, and mucositis). Sex-tailored CRC chemotherapy treatment is necessary to obtain efficacy avoiding toxicity, based on patients' biological and genetic characteristics, a vision that would change CRC setting, a stable disease but still orphan of a real tailored approach.
Keyphrases
- chemotherapy induced
- locally advanced
- end stage renal disease
- newly diagnosed
- chronic pain
- chronic kidney disease
- peritoneal dialysis
- oxidative stress
- smoking cessation
- neuropathic pain
- emergency department
- squamous cell carcinoma
- prognostic factors
- radiation induced
- healthcare
- genome wide
- spinal cord injury
- rectal cancer
- patient reported
- spinal cord
- patient reported outcomes